Chitapanarux Imjai, Sripan Patumrat, Somwangprasert Areewan, Charoentum Chaiyut, Onchan Wimrak, Watcharachan Kirati, Wongmaneerung Panchaporn, Kongmebhol Pailin, Jia-Mahasap Bongkot, Huntrakul Lalita
Division of Radiation Oncology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. Email:
Northern Thai Research Group of Radiation Oncology (NTRG-RO), Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Asian Pac J Cancer Prev. 2019 Sep 1;20(9):2699-2706. doi: 10.31557/APJCP.2019.20.9.2699.
Objective: This study was attempted to investigate overall survival by stage at diagnosis in female breast cancer patients in Northern Thailand by using 2 different staging systems; namely, American Joint Committee on Cancer (AJCC) Tumor (T), Nodal (N) and Metastatic (M) staging system and Surveillance Epidemiology and End Results (SEER) summary staging system. Methods: We studies female breast cancer patients whose data were registered in Chiang Mai cancer registries between January 2006 and December 2015. Data were recorded in SEER summary staging system. The TNM AJCC staging was searched in the medical records. Results: A total of 3,873 female breast cancer patients were diagnosed from 2006-2015. All data sets were recorded in SEER summary stage 2000. Early stage was the most prevalent stage at the time of diagnosis (58%), followed by loco-regional advanced stage (32%), and metastatic breast cancer (10%). The 5-year overall survival rate of early, loco-regional advanced, and metastatic stages were 85.3%, 66.4%, and 26.2%, respectively. After examining the medical records, we excluded patients who had no data on T, N, and M in their records. Finally, only 3,251 patients were analyzed for AJCC stage-specific survival. The 5-year overall survival rate in stages I, II, III, and IV were 94.4%, 85.0%, 56.6%, and 28.3%, respectively. Conclusion: Comparing to more stable economic countries, the 5-year overall survival rate for a specific stage of breast cancer in Northern Thailand was slightly lower in early stage and stage I-II in accordance with AJCC, but much lower in loco-regional stage and stage III with respect to AJCC. Nevertheless, it was similar in metastatic stage and stage IV according to AJCC.
本研究试图通过使用两种不同的分期系统，即美国癌症联合委员会（AJCC）肿瘤（T）、淋巴结（N）和转移（M）分期系统以及监测、流行病学和最终结果（SEER）总结分期系统，来调查泰国北部女性乳腺癌患者诊断时分期的总生存率。方法：我们研究了2006年1月至2015年12月期间在清迈癌症登记处登记数据的女性乳腺癌患者。数据记录在SEER总结分期系统中。在病历中查找TNM AJCC分期。结果：2006年至2015年共诊断出3873例女性乳腺癌患者。所有数据集均记录在SEER 2000总结分期中。早期是诊断时最常见的阶段（58%），其次是局部区域晚期阶段（32%）和转移性乳腺癌（10%）。早期、局部区域晚期和转移性阶段的5年总生存率分别为85.3%、66.4%和26.2%。在检查病历后，我们排除了病历中没有T、N和M数据的患者。最后，仅对3251例患者进行了AJCC分期特异性生存分析。I期、II期、III期和IV期的5年总生存率分别为94.4%、85.0%、56.6%和28.3%。结论：与经济更稳定的国家相比，泰国北部乳腺癌特定阶段的5年总生存率在早期和根据AJCC的I-II期略低，但在局部区域阶段和根据AJCC的III期则低得多。然而，根据AJCC，在转移性阶段和IV期则相似。
